^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | INCB86550 (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors
Published date:
11/08/2022
Excerpt:
...138 patients received INCB086550 treatment at doses ranging from 100 mg once daily to 800 mg twice daily (bid); median age was 65 years (range, 31–86), 60.9% were women, 80.4% were white….Two patients (1.4%) achieved a complete response (squamous cell anal cancer, 400 mg bid; MSI-H colorectal cancer, 400 mg bid)...
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0774
Trial ID:
